215 related articles for article (PubMed ID: 15279838)
21. Construction of a human cytochrome P450 1A1: rat NADPH-cytochrome P450 reductase fusion protein cDNA and expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification.
Chun YJ; Shimada T; Guengerich FP
Arch Biochem Biophys; 1996 Jun; 330(1):48-58. PubMed ID: 8651703
[TBL] [Abstract][Full Text] [Related]
22. Metabolic activation of aromatic amine mutagens by simultaneous expression of human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and N-acetyltransferase in Escherichia coli.
Josephy PD; Evans DH; Parikh A; Guengerich FP
Chem Res Toxicol; 1998 Jan; 11(1):70-4. PubMed ID: 9477228
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocylic amines.
Kamataki T; Suzuki A; Kushida H; Iwata H; Watanabe M; Nohmi T; Fujita K
Cancer Lett; 1999 Sep; 143(2):113-6. PubMed ID: 10503888
[TBL] [Abstract][Full Text] [Related]
24. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
25. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009.
Shimada T; Oda Y; Gillam EM; Guengerich FP; Inoue K
Drug Metab Dispos; 2001 Sep; 29(9):1176-82. PubMed ID: 11502724
[TBL] [Abstract][Full Text] [Related]
26. Mutagenicity of cytochrome P450 2E1 substrates in the Ames test with the metabolic competent S. typhimurium strain YG7108pin3ERb5.
Emmert B; Bünger J; Keuch K; Müller M; Emmert S; Hallier E; Westphal GA
Toxicology; 2006 Nov; 228(1):66-76. PubMed ID: 16978761
[TBL] [Abstract][Full Text] [Related]
27. Mutagenicity of aromatic amines and amides with chemical models for cytochrome P450 in Ames assay.
Inami K; Okazawa M; Mochizuki M
Toxicol In Vitro; 2009 Sep; 23(6):986-91. PubMed ID: 19563884
[TBL] [Abstract][Full Text] [Related]
28. Nitrogen-substitution effects on the mutagenicity and cytochrome P450 isoform-selectivity of chrysene analogs.
Yamada K; Hakura A; Kato TA; Mizutani T; Saeki K
Mutat Res; 2005 Sep; 586(1):87-95. PubMed ID: 16087391
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome b(5) coexpression increases the CYP2E1-dependent mutagenicity of dialkylnitrosamines in methyltransferase-deficient strains of Salmonella typhimurium.
Cooper MT; Porter TD
Mutat Res; 2001 Dec; 484(1-2):61-8. PubMed ID: 11733072
[TBL] [Abstract][Full Text] [Related]
30. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli.
Iwata H; Fujita K; Kushida H; Suzuki A; Konno Y; Nakamura K; Fujino A; Kamataki T
Biochem Pharmacol; 1998 Apr; 55(8):1315-25. PubMed ID: 9719488
[TBL] [Abstract][Full Text] [Related]
31. Bioactivation of the heterocyclic aromatic amine 2-amino-3-methyl-9H-pyrido [2,3-b]indole (MeAalphaC) in recombinant test systems expressing human xenobiotic-metabolizing enzymes.
Glatt H; Pabel U; Meinl W; Frederiksen H; Frandsen H; Muckel E
Carcinogenesis; 2004 May; 25(5):801-7. PubMed ID: 14729582
[TBL] [Abstract][Full Text] [Related]
32. High promutagen activating capacity of yeast microsomes containing human cytochrome P-450 1A and human NADPH-cytochrome P-450 reductase.
Sengstag C; Eugster HP; Würgler FE
Carcinogenesis; 1994 May; 15(5):837-43. PubMed ID: 8200084
[TBL] [Abstract][Full Text] [Related]
33. Development of a high-throughput genotoxicity assay using Umu test strains expressing human cytochrome P450s and NADPH-P450 reductase and bacterial O-acetyltransferase.
Hori H; Hirata D; Fujii W; Oda Y
Environ Mol Mutagen; 2017 May; 58(4):209-216. PubMed ID: 28436560
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba.
Liu KH; Kim MJ; Jeon BH; Shon JH; Cha IJ; Cho KH; Lee SS; Shin JG
J Clin Pharm Ther; 2006 Feb; 31(1):83-91. PubMed ID: 16476124
[TBL] [Abstract][Full Text] [Related]
35. Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines.
Duarte MP; Palma BB; Laires A; Oliveira JS; Rueff J; Kranendonk M
Mutagenesis; 2005 May; 20(3):199-208. PubMed ID: 15843388
[TBL] [Abstract][Full Text] [Related]
36. Chemical models for cytochrome P450 as a biomimetic metabolic activation system in mutation assays.
Inami K; Mochizuki M
Mutat Res; 2002 Aug; 519(1-2):133-40. PubMed ID: 12160898
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of CYP2A6 in relation to cancer.
Kamataki T; Nunoya K; Sakai Y; Kushida H; Fujita K
Mutat Res; 1999 Jul; 428(1-2):125-30. PubMed ID: 10517986
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
39. Effect of chrysin, a flavonoid compound, on the mutagenic activity of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP) and benzo(a)pyrene (B(a)P) in bacterial and human hepatoma (HepG2) cells.
Uhl M; Ecker S; Kassie F; Lhoste E; Chakraborty A; Mohn G; Knasmüller S
Arch Toxicol; 2003 Aug; 77(8):477-84. PubMed ID: 12856103
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of promutagens catalyzed by Drosophila melanogaster CYP6A2 enzyme in Saccharomyces cerevisiae.
Saner C; Weibel B; Wurgler FE; Sengstag C
Environ Mol Mutagen; 1996; 27(1):46-58. PubMed ID: 8625948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
